References
- List A, Kurtin S, Roe D J, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005; 352: 549–557
- List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465
- Bartlett J B, Dredge K, Dalgleish A G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004; 4: 314–322
- Dredge K, Horsfall R, Robinson S P, Zhang L H, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 2005; 69: 56–63
- Celgene Corporation. Revlimid®: lenalidomide 5 mg, 10 mg, 15 mg and 25 mg capsules. Available from: http://www.celgene.com/PDF/RevlimidPI.pdf (accessed on 12 September 2007)
- Niesvizky R, Naib T, Christos P J, Jayabalan D, Furst J R, Jalbrzikowski J, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007; 138: 640–643
- Richardson P G, Schlossman R L, Weller E, Hideshima T, Mitsiades C, Davies F, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063–3067
- Richardson P G, Blood E, Mitsiades C S, Jagannath S, Zeldenrust S R, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458–3464
- Greenberg P, Cox C, LeBeau M M, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
- National Cancer Institute common terminology criteria for adverse events v 3.0. Available from: http://ctep.cancer.gov/forms/CTCAEv3.pdf. (accessed on 5 November 2007)
- Grudeva-Popova J. New options in the treatment of myelodysplastic syndrome. J BUON 2005; 10: 35–42
- List A F, Baker A F, Green S, Bellamy W. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. Cancer Control 2006; 13: 4–11
- Cheson B D, Greenberg P L, Bennett J M, Lowenberg B, Wijermans P W, Nimer S D, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425
- Chen N, Lau H, Kong L, Kumar G, Zeldis J B, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007, [Epub ahead of print]
- Nangaku M, Eckardt K U. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261–268
- List A F, Estes M, Williams A, Sekharam M, Ozawa U, Gao G, et al. Lenalidomide (CC-5013; Revlimid®) promotes erythropoiesis in myelodysplastic syndromes (MDS) by CD45 protein tyrosine phosphatase (PTP) inhibition. Blood 2006; 108, Abstract 1360